Janssen Korea targets 210 billion won sales

Published: 2009-01-28 06:57:00

Updated: 2009-01-28 06:57:00

Janssen Korea has set a goal of 210 billion won in sales this year, with its ambitious plan to launch four new drugs, such as Intelence, Jurnista, Invega and Yondelis.

- Intelence (etravirine) is a drug used for the treatment of HIV. Intelence is a non-nucleoside reverse transcriptase inhibito...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK